NAMS, NAMSW · CIK 0001936258 · operating
NewAmsterdam Pharma is a late-stage biopharmaceutical company focused on developing therapies for cardiometabolic diseases. Headquartered in Naarden, the Netherlands, the company operates with approximately 100 full-time employees and is listed on Nasdaq.
The company's primary development program is Obicetrapib, an oral cholesteryl ester transfer protein (CETP) inhibitor administered at low doses. Obicetrapib is being evaluated in multiple clinical trials as both a standalone treatment and in combination with ezetimibe for lowering LDL cholesterol in patients with cardiovascular disease. The company is also exploring Obicetrapib's potential in neurodegenerative disease, with a Phase 2a trial underway for Alzheimer's disease.
As a clinical-stage company, NewAmsterdam Pharma has not generated meaningful revenue from product sales. The company is primarily funded through capital raises and operates in the Netherlands while pursuing regulatory pathways in major pharmaceutical markets through its Nasdaq listing.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $-1.72 | $-1.72 | +32.8% | |
| 2024 | $-2.56 | $-2.56 | -19.1% | |
| 2023 | $-2.15 | $-2.15 | — |